Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 20/20 | 0.75 |
| ▸ | RARA | P10276 | 1/20 | 0.75 |
| ▸ | RARB | P10826 | 1/20 | 0.75 |
| ▸ | RARG | P13631 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2655428 | 1.00 | GCK (0.75) | GCKRARARARBRARG | |
| SCHEMBL5430637 | 0.93 | GCK (0.73) | GCKRARARARBRARG | |
| SCHEMBL5435282 | 0.93 | GCK (0.88) | GCKRARARARBRARG | |
| SCHEMBL2655429 | 0.91 | GCK (0.70) | GCKRARARARBRARG | |
| SCHEMBL2651714 | 0.91 | GCK (0.85) | GCKRARARARBRARG | |
| SCHEMBL2652506 | 0.89 | GCK (0.81) | GCKRARARARBRARG | |
| SCHEMBL14366903 | 0.89 | GCK (0.88) | GCKRARARARBRARG | |
| SCHEMBL14520614 | 0.88 | GCK (0.88) | GCKRARARARBRARG | |
| SCHEMBL14520615 | 0.88 | GCK (0.88) | GCKRARARARBRARG | |
| SCHEMBL14520621 | 0.87 | GCK (0.75) | GCKRARARARBRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062351-A1 | Benzoyl amino pyridyl carboxylic acid derivatives useful as glucokinase (glk) activators | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| US-20090062351-A1 | Benzoyl amino pyridyl carboxylic acid derivatives useful as glucokinase (glk) activators | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| US-20090062351-A1 | Benzoyl amino pyridyl carboxylic acid derivatives useful as glucokinase (glk) activators | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| US-20090018157-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | US | disclosed |
| US-20090018157-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | US | disclosed |
| US-20090018157-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | US | disclosed |
| EP-1689741-B1 | BENZOYL AMINO PYRIDYL CARBOXYLIC ACID DERIVATIVES AS GLUCOKINASE ACTIVATORS | ASTRAZENECA AB (SE) | 2008-02-13 | — | — | EP | disclosed |
| US-20070255062-A1 | Benzoyl Amino Pyridyl Carboxylic Acid Derivatives Useful as Glucokinase (Glk) Activators | ASTRAZENECA AB (SE) | 2007-11-01 | — | — | US | disclosed |
| US-20070255062-A1 | Benzoyl Amino Pyridyl Carboxylic Acid Derivatives Useful as Glucokinase (Glk) Activators | ASTRAZENECA AB (SE) | 2007-11-01 | — | — | US | disclosed |
| US-20070255062-A1 | Benzoyl Amino Pyridyl Carboxylic Acid Derivatives Useful as Glucokinase (Glk) Activators | ASTRAZENECA AB (SE) | 2007-11-01 | — | — | US | disclosed |
| US-20070078168-A1 | PYRIDINE CARBOXYLIC ACID DERIVATIVES AS GLUCOKINASE MODULATORS | ASTRAZENECA AB (SE) | 2007-04-05 | — | — | US | disclosed |
| US-20070078168-A1 | PYRIDINE CARBOXYLIC ACID DERIVATIVES AS GLUCOKINASE MODULATORS | ASTRAZENECA AB (SE) | 2007-04-05 | — | — | US | disclosed |
| US-20070078168-A1 | PYRIDINE CARBOXYLIC ACID DERIVATIVES AS GLUCOKINASE MODULATORS | ASTRAZENECA AB (SE) | 2007-04-05 | — | — | US | disclosed |
| EP-1682509-A1 | PYRIDINE CARBOXYLIC ACID DERIVATIVES AS GLUCOKINASE MODULATORS | AstraZeneca AB (SE) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005044801-A1 | PYRIDINE CARBOXYLIC ACID DERIVATIVES AS GLUCOKINASE MODULATORS | ASTRAZENECA AB (SE) | 2005-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018157-A1 | Chemical compounds | GALK1, GCK, GRK1 | GCK 2/4885RARA 3816/4885RARB 3780/4885 |
| US-20070078168-A1 | PYRIDINE CARBOXYLIC ACID DERIVATIVES AS GLUCOKINASE MODULATORS | GCK, GCKR, GALK1 | GCK 1/4885RARA 2455/4885RARB 2687/4885 |
| US-20070255062-A1 | Benzoyl Amino Pyridyl Carboxylic Acid Derivatives Useful as Glucokinase (Glk) Activators | GCK, GALK1, PDXK | GCK 1/4885RARA 3021/4885RARB 3592/4885 |
| US-20090062351-A1 | Benzoyl amino pyridyl carboxylic acid derivatives useful as glucokinase (glk) activators | GCK, GCKR, GALK1 | GCK 1/4885RARA 2075/4885RARB 2040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.